European Heart Journal vs Gut: Which Journal Should You Choose?

EHJ asks whether the paper matters across cardiology. Gut asks whether the paper is one of the strongest digestive-disease papers in the field.

That's the real split.

EHJ submission's editorial guidance stresses broad cardiovascular importance, European relevance, ESC guideline integration, and strong methodological credibility. Gut's editorial guidance stress translational significance, a strong "Significance of this study" box, mechanistic depth, and practical GI or hepatology relevance.

So if your paper needs cardiology context to feel important, it belongs closer to EHJ. If it needs GI, liver, microbiome, or digestive-disease context to feel complete, it belongs closer to Gut.

EHJ wins when the paper is truly cardiovascular.

That usually means:

• cardiovascular outcomes are the headline, not a secondary layer
• the audience should be general cardiologists, not only one organ-specific specialty
• the work has clear practice, policy, or guideline implications
• the paper becomes stronger when framed around cardiovascular risk, treatment, prevention, or outcomes

Examples include:

• cardiometabolic studies where the cardiovascular endpoint is the real consequence
• vascular-risk papers tied to inflammatory disease when cardiology management is central
• arrhythmia, heart-failure, imaging, or prevention work in GI-related populations where cardiologists are the people who need to act

EHJ's editorial guidance is very clear on one point: the journal doesn't reward narrow specialty stories just because they're technically strong. It rewards consequence that reaches across cardiology.

Gut wins when the paper is fundamentally a digestive-disease or hepatology study.

That includes:

• microbiome, inflammatory bowel disease, hepatology, or GI oncology work with strong mechanistic or translational value
• digestive-disease studies where the field-specific biology matters to understanding the result
• papers that need GI framing, disease-specific context, and more translational narrative than a general cardiology journal would carry
• work whose most natural readers are gastroenterologists, hepatologists, and translational digestive-disease researchers

Gut's editorial guidance emphasize this repeatedly. Gut likes papers that connect bench science to clinical consequence, but it still wants the problem to feel central to digestive disease.

EHJ's editorial guidance highlights large registries, ESC relevance, and European practice implications. Even strong studies can get rejected early if they feel too local, too organ-specific, or too detached from general cardiovascular consequence.

Gut's editorial guidance makes clear that descriptive work, especially descriptive microbiome work, isn't enough. The journal wants a meaningful mechanistic or clinical message that can be articulated quickly.

One of the more practical facts from the Gut submission guide is the editorial importance of the "Significance of this study" box. That means the paper's why-now and why-it-matters logic has to be unusually sharp before review.

The EHJ submission material repeatedly pushes authors to explain how the work changes cardiovascular thinking or care. That's a clue that inflammatory or organ-interaction papers belong there only when the cardiovascular consequence is truly the center of gravity.

• the manuscript is fundamentally a cardiovascular paper
• the main readers should be cardiologists
• the strongest consequence is in cardiovascular practice, outcomes, prevention, or guideline logic
• the paper gets stronger when written in general cardiology language

That's the EHJ lane.

• the manuscript is fundamentally about gastroenterology, hepatology, or digestive-disease biology
• the main readers should be GI or liver specialists
• the work depends on translational digestive-disease framing
• the paper gets stronger when written for a broad GI readership rather than a cardiology readership

That's the Gut lane.

These often confuse teams. If the paper is mainly about microbiome biology with cardiovascular implications, Gut is usually the cleaner fit. If the main claim is how cardiovascular risk prediction or management should change, EHJ becomes more plausible.

Again, the deciding factor is the audience. A paper about cardiovascular complications in liver disease can be an EHJ paper if cardiologists are the decision-makers who need the message. If the work is fundamentally about liver-disease biology or hepatology management, Gut is often more natural.

If a GI therapy has important cardiovascular safety implications, or a cardiovascular drug has important GI implications, ask which field needs the result first. That usually resolves the split faster than prestige comparisons do.

This isn't a simple top-down cascade.

A paper rejected by EHJ does not automatically become a good Gut paper, because Gut has its own strict editorial logic. It only becomes a sensible move if the real problem was that the manuscript was too specialty-defined for a general cardiology flagship, while still being strong enough for a top-tier GI journal.

The reverse is also true. A paper rejected by Gut because it isn't sufficiently GI-defined doesn't suddenly become a good EHJ paper unless the cardiovascular consequence is genuinely broader than the digestive-disease context.

If the paper only feels important once the reader is already deep in GI or liver disease context, EHJ becomes much harder.

Gut's editorial guidance is explicit here. Descriptive studies, especially descriptive microbiome or association papers, don't survive well unless the translational or mechanistic payoff is concrete.

If a paper is really for one narrow subspecialty but the cover letter tries to inflate it into a field-wide cardiovascular event, the mismatch shows quickly.

If the paper is really better for a narrower venue but has been polished upward only because Gut looks attractive, that usually shows too.

A strong EHJ first page makes the cardiovascular implication obvious immediately. The cardiology reader should understand why the result matters before getting deep into the organ-specific context.

A strong Gut first page makes the digestive-disease consequence obvious immediately. The editor should see translational importance, mechanistic relevance, or practical GI consequence within the opening frame.

If the same manuscript can't do one of those cleanly, it may still be under-positioned.

Try finishing one of these sentences:

• "this changes what cardiologists should do, or how they should interpret risk" points toward European Heart Journal
• "this changes what gastroenterologists or hepatologists should do, or how they should interpret disease biology" points toward Gut

Whichever sentence feels more natural usually identifies the better first target.

Send to European Heart Journal first if:

1. the manuscript is fundamentally cardiovascular
2. cardiologists are the primary audience
3. the paper has broad cardiovascular consequence
4. GI or liver context matters, but doesn't define the whole paper

Send to Gut first if:

1. the manuscript is fundamentally digestive-disease or liver focused
2. GI readers are the primary audience
3. translational or mechanistic GI importance is central
4. cardiovascular implications are important, but still secondary to the GI story